| 96.92 2.63 (2.79%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 115.03  |
1-year : | 134.36 |
| Resists | First : | 98.48 |
Second : | 115.03 |
| Pivot price | 88.56 |
|||
| Supports | First : | 80.24 |
Second : | 68.97 |
| MAs | MA(5) : | 94.47 |
MA(20) : | 86.19 |
| MA(100) : | 74.9 |
MA(250) : | 59.75 |
|
| MACD | MACD : | 5.6 |
Signal : | 4.9 |
| %K %D | K(14,3) : | 94  |
D(3) : | 94.8 |
| RSI | RSI(14): 75.2 |
|||
| 52-week | High : | 98.48 | Low : | 36.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MIRM ] has closed below upper band by 17.8%. Bollinger Bands are 152.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 98.6 - 98.99 | 98.99 - 99.33 |
| Low: | 92.18 - 92.65 | 92.65 - 93.05 |
| Close: | 96.09 - 96.87 | 96.87 - 97.55 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mon, 26 Jan 2026
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Investing News Network
Mon, 26 Jan 2026
Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Mon, 26 Jan 2026
Baird updates Mirum Pharmaceuticals (MIRM) valuation following beat-and-raise earnings results - MSN
Sun, 25 Jan 2026
How Investors May Respond To Mirum Pharmaceuticals (MIRM) 2026 Revenue Guidance Centered On Existing Drugs And Pipeline - simplywall.st
Fri, 23 Jan 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $86,423.58 in Stock - MarketBeat
Fri, 23 Jan 2026
Christopher Peetz Sells 7,098 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.394e+007 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 7,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.757e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8.8 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | -3.6 % |
| Qtrly Rev. Growth | 4.7179e+008 % |
| Gross Profit (p.s.) | 96.32 |
| Sales Per Share | -32.27 |
| EBITDA (p.s.) | 7.69469e+008 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 45 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 310.9 |
| Price to Book value | 0 |
| Price to Sales | -3.01 |
| Price to Cash Flow | 8.34 |
| Dividend | 0 |
| Forward Dividend | 8.36e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|